Peroxovanadate and insulin action in adipocytes from NIDDM patients. Evidence against a primary defect in tyrosine phosphorylation

Diabetologia

Volumn 40, Issue 10, 1997, Pages 1197-1203

  Yu, Z W ^a,b   Jansson, P A ^a   Posner, B I ^c   Smith, U ^a   Eriksson, J W ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Adipocyte; CAMP; Glucose uptake; In vitro; Insulin; Isoprenaline; Lipolysis; NIDDM; Peroxovanadate; Tyrosine phosphorylation

Indexed keywords

8 BROMO CYCLIC AMP; INSULIN; INSULIN RECEPTOR; ISOPRENALINE; PEROXIDE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RECEPTOR SUBUNIT; TYROSINE; VANADIC ACID;

ADIPOCYTE; ADULT; ARTICLE; BETA ADRENERGIC STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOLYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ADIPOCYTES; ADRENERGIC BETA-AGONISTS; ADULT; ANIMALS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISOPROTERENOL; LIPOLYSIS; MALE; MICE; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR, INSULIN; TYROSINE; VANADATES;

EID: 0030874014     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050807     Document Type: Article

References (33)

1. Shechter Y (1990) Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes 39: 1-5
2. Cam MC, Pederson RA, Brownsey RW, McNeill JH (1993) Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats. Diabetologia 36: 218-224
3. Heyliger CE, Tahiliant AG, McNeill JH (1985) Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227: 1474-1476
4. Halberstam M, Cohen N, Shlimovich P, Rossetii L, Shamoon H (1996) Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 45: 659-666
5. Shisheva A, Shechter Y (1993) Mechanism of pervanadate stimulation and potentiation of insulin-activated glucose transport in rat adipocytes: dissociation from vanadate effect. Endocrinology 133: 1562-1568
6. Yu Z-W, Posner BI, Smith U, Eriksson JW (1996) Effects of vanadate and peroxovanadate on insulin binding, degradation and sensitivity in rat adipocytes. Biochim Biophys Acta 1310: 103-109
7. Eriksson JW, Lönnroth P, Smith U (1992) Vanadate increases cell surface insulin binding and improves insulin sensitivity in both normal and insulin-resistant rat adipocytes. Diabetologia 35: 510-516
8. Posner BI, Faure R, Burgess JW, et al. (1994) Peroxovanadium compounds: a new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596-4604
9. Bernier M, Larid DM, Lane MD (1988) Effect of vanadate on the cellular accumulation of pp15, an apparent product of insulin receptor tyrosine kinase action. J Biol Chem 263: 13625-13634
10. Lönnroth P, Eriksson JW, Posner BI, Smith U (1993) Peroxovanadate but not vanadate exerts insulin-like effects in human adipocytes. Diabetologia 36: 113-116
11. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1595-1607
12. Arner P, Bolinder J, Engfeldt P, Östman J (1980) The antilipolytic effect of insulin in human adipose tissue in obesity, diabetes mellitus, hyperinsulinemia, and starvation. Metabolism 30: 753-760
13. Shechter Y (1984) Trifluoperazine inhibits insulin action on glucose metabolism in fat cells without affecting inhibition of lipolysis. Proc Natl Acad Sci USA 81: 327-331
14. Howard BV, Savage PJ, Nagulesparan M, Bennion LJ, Unger RH, Bennett PH (1979) Evidence for marked sensitivity to the antilipolytic action of insulin in obese maturity-onset diabetics. Metabolism 28: 744-750
15. Foley JE, Kashiwagi A, Verso MA, Reaven G, Andrews J (1983) Improvement in in vitro insulin action after one month of insulin therapy in obese noninsulin-dependent diabetics: measurements of glucose transport and metabolism, insulin binding, and lipolysis in isolated adipocytes. J Clin Invest 72: 1901-1909
16. Lönnroth P, Digirolamo M, Krotkiewski M, Smith U (1983) Insulin binding and responsiveness in fat cells from patients with reduced glucose tolerance and type II diabetes. Diabetes 32: 748-754
17. Olefsky JM (1993) Insulin resistance and the pathogenesis of non-insulin dependent diabetes mellitus: cellular and molecular mechanisms. In: Östenson CG, Efendic S, Vranic M (eds) New concepts in the pathogenesis of NIDDM. Plenum Press, New York, pp 129-150
18. Eriksson JW, Lönnroth P, Posner BI, Shaver A, Wesslau C, Smith UPG (1996) A stable peroxovanadium compound with insulin-like action in human fat cells. Diabetologia 39: 235-242
19. Smith U, Sjöström L, Björntorp P (1972) Comparison of two methods for determining human adipose cell size. J Lipid Res 13: 822-824
20. Bradley DC, Kaslow HR (1989) Radiometric assays for glycerol, glucose, and glycogen. Anal Biochem 180: 11-16
21. Lafontan M, Berlan M (1993) Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34: 1057-1091
22. Reynisdottir S, Ellerfeldt K, Wahrenberg H, Lithell H, Arner P (1994) Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J Clin Invest 93: 2590-2599
23. Reynisdottir S, Eriksson M, Angelin B, Arner P (1995) Impaired activation of adipocyte lipolysis in familial combined hyperlipidaemia. J Clin Invest 95: 2161-2169
24. Ueki H, Okuhama R, Sera M, Inoue T, Tominaga N, Morita T (1992) Stimulatory effect of vanadate on 3′,5′-cyclic guanosine monophosphate-inhibited low Michaelis-Menten constant 3′,5′-cyclic adenosine monophosphate phosphodiesterase activity in isolated rat fat pads. Endocrinology 131: 441-446
25. Lönnroth P, Smith U (1986) The antilipolytic effect of insulin in human adipocytes requires activation of the phosphodiesterase. Biochem Biophys Res Commun 141: 1157-1161
26. Manganiello VC, Smith CJ, Degerman E, Vasta V, Tornqvist H, Belfrage P (1991) Molecular mechanisms involved in the antilipolytic action of insulin: phosphorylation and activation of a particulate adipocyte cAMP phosphodiesterase. In: Raizada MK, LeRoith D (eds) Molecular biology and physiology of insulin and insulin-like growth factors. Plenum Press, New York, pp 239-248
27. Yki-Järvinen H, Taskinen M-R (1988) Interrelationships among insulin's antilipolytic and glucoregulatory effects and plasma triglycerides in nondiabetic and diabetic patients with endogenous hypertriglyceridemia. Diabetes 37: 1271-1278
28. Smith U, Lager I (1989) Insulin-antagonistic effects of counterregulatory hormones: clinical and mechanistic aspects. Diabetes Metab Rev 5: 511-525
29. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP (1991) Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 87: 1072-1081
30. Thies RS, Molina JM, Ciaraldi TP, Freidenberg GR, Olefsky JM (1990) Insulin-receptor autophosphorylation and endogenous substrate phosphorylation in human adipocytes from control, obese, and NIDDM subjects. Diabetes 39: 250-259
31. Sinha MK, Pories WJ, Flickinger EG, Meelheim D, Caro JF (1987) Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes 36: 620-625
32. Yu Z-W, Wickman A, Eriksson JW (1996) Cryptic receptors for insulin-like growth factor II in the plasma membrane in rat adipocytes - a possible link to cellular insulin resistance. Biochim Biophys Acta 1282: 57-62
33. Vannucci SJ, Nishimura H, Satoh S, Cushman SW, Holman GD, Simpson IA (1992) Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells: modulation by isoprenaline and adenosine. Biochem J 288: 325-330